Bayer Aktiengesellschaft (ETR:BAYN)
Germany · Delayed Price · Currency is EUR | Market Cap | 48.39B +74.4% |
| Revenue (ttm) | 45.38B -1.7% |
| Net Income | -1.74B |
| EPS | -1.77 |
| Shares Out | 982.42M |
| PE Ratio | n/a |
| Forward PE | 10.57 |
| Dividend | 0.11 (0.22%) |
| Ex-Dividend Date | Apr 27, 2026 |
| Volume | 456,367 |
| Open | 49.20 |
| Previous Close | 49.26 |
| Day's Range | 48.72 - 49.53 |
| 52-Week Range | 25.78 - 53.92 |
| Beta | 0.83 |
| Analysts | Buy |
| Price Target | 57.94 (+18.05%) |
| Earnings Date | Nov 3, 2026 |
About Bayer Aktiengesellschaft
Bayer Aktiengesellschaft operates as a life science company in Europe, the Middle East, Africa, Germany, Switzerland, North America, the United States, the Asia Pacific, China, Latin America, and Brazil. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment provides prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and ge... [Read more]
Financial Performance
In 2025, Bayer Aktiengesellschaft's revenue was 45.58 billion, a decrease of -2.21% compared to the previous year's 46.61 billion. Losses were -3.62 billion, 41.8% more than in 2024.
Financial StatementsAnalyst Summary
According to 18 analysts, the average rating for BAYN stock is "Buy." The 12-month stock price target is €57.94, which is an increase of 18.05% from the latest price.
News
U.S. FDA Grants Accelerated Approval to Bayer’s HYRNUO (sevabertinib) as a First-Line Targeted Therapy for Patients with HER2-Mutated Non-Small Cell Lung Cancer
Bayer announced today that following Priority Review and Breakthrough Therapy Designation, the U.S. Food and Drug Administration (FDA) has granted accelerated approval for HYRNUO (sevabertinib), for t...
U.S. FDA Grants Accelerated Approval to Bayer's HYRNUO® (sevabertinib) as a First-Line Targeted Therapy for Patients with HER2-Mutated Non-Small Cell Lung Cancer
WHIPPANY, N.J.--(BUSINESS WIRE)--U.S. FDA Grants Accelerated Approval to Bayer's HYRNUO® (sevabertinib) as a First-Line Targeted Therapy for Patients with HER2-Mutated NSCLC.
Bayer and Neste Close Commercial Agreement to Jointly Scale newgold Winter Canola for Biofuels Production
Commitment aims to support the growth of winter canola in the Southern Great Plains of the U.S., as a feedstock for renewable diesel and sustainable aviation fuel Bayer and Neste, the world's lead...
Bayer and Neste Close Commercial Agreement to Jointly Scale newgold® Winter Canola for Biofuels Production
MONHEIM, Germany & ST. LOUIS--(BUSINESS WIRE)--Bayer and Neste, the world's leading producer of renewable diesel and sustainable aviation fuel, have finalized a commercial agreement to jointly scale B...
BAYER INITIATES PHASE II STUDY OF INVESTIGATIONAL GIRK4 INHIBITOR IN PATIENTS WITH ATRIAL FIBRILLATION
WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer announced today the initiation of a global Phase II clinical trial (NCT07625215) evaluating BAY 3670549, an investigational highly selective G-protein-coupled in...
BAYER AG: AskBio's Viralgen,EpilepsyGTx Partner To Advance AAV Gene Therapy For Epilepsy
(RTTNews) - EpilepsyGTx, a biotechnology company focused on gene therapies for drug-resistant epilepsy, has entered into a collaboration with Viralgen, a leading AAV contract development and manufactu...
Bayer Crop Science Targets €3B Cash Flow by 2029 With Seeds-Led Growth
Bayer Aktiengesellschaft ETR: BAYN outlined progress on its Crop Science division's five-year framework at a 2026 innovation event in Iowa, reaffirming targets for above-market sales growth, a mid-20s...
Bayer Aktiengesellschaft Transcript: Investor update
A comprehensive update confirmed progress on the Five-Year Framework, with strong execution in margin expansion, cash productivity, and innovation-driven growth. Corn remains the main growth engine, while differentiated strategies across platforms and robust R&D underpin above-market growth and margin ambitions through 2029.
Bayer Aktiengesellschaft Press release: Investor update
Bayer Aktiengesellschaft issued a press release on September 2, 2026, disclosing material business information to investors.
Bayer Aktiengesellschaft Slides: Investor update
Bayer Aktiengesellschaft has posted slides in relation to its latest quarterly earnings report, which was published on September 2, 2026.
Bayer says Crop Science unit makes progress on product launches
Bayer said on Wednesday its Crop Science business had introduced two out of 10 planned new products with peak annual sales of at least €500 million ($579 million) each and mapped out further market...
Bayer Advances Combined Seed and Crop Protection Pipeline and Enters Phase of Blockbuster Launches
HUXLEY, Iowa--(BUSINESS WIRE)--Bayer is implementing its previously announced ambition to bring 10 blockbusters to market over 10 years, beginning to launch major Crop Science innovations in key agric...
Living Security: Human Risk Management Leaders from Reveal Risk, Bayer, and Labcorp to Speak at HRMCon 2026
Enterprise CISOs and cybersecurity leaders will share real-world lessons for strengthening Workforce Security, advancing Security Behavior Management, and reducing risk across humans and AI agents ...
Trump reportedly plans to announce new drug pricing deals with nearly a dozen drugmakers
Nearly a dozen drugmakers are reportedly slated to voluntarily sell their medications at lower prices under deals expected to be announced by President Donald Trump on Monday. The string of deals buil...
Trump administration to announce drug pricing deals
U.S. President Donald Trump is expected to announce a new round of drug-pricing agreements on Monday, a White House official said, part of a push to make healthcare more affordable for Americans.
Bayer's Phase 3 REVEAL Study Of I 124 Evuzamitide Meets Primary Goals In Cardiac Amyloidosis
(RTTNews) - Bayer AG (BAYN.DE, BYR.L) announced results from the Phase III REVEAL study, evaluating investigational positron emission tomography (PET) radiotracer iodine 124 evuzamitide (I 124 evuzami...
Bayer announces presentation of results from Phase III REVEAL study
Bayer (BAYRY) announced the presentation of first detailed results from the Phase III REVEAL study, an investigator-initiated study by Brigham and Women’s Hospital, that evaluated the investigational ...
Bayer's $7.25 Billion Roundup Plan Survives Another Court Detour
Bayer's $7.25 Billion Roundup Plan Survives Another Court Detour
U.S. court dismisses appeal over objections to $7.25 billion Roundup deal
The 8th U.S. Circuit Court of Appeals on Thursday dismissed a challenge by a group of plaintiffs who opposed Bayer's effort to resolve tens of thousands of Roundup lawsuits through a $7.25 billion sta...
Four firms control more than half of the world’s seed supply. Italian farmers are fighting back and returning to the bartering system
Bayer, Corteva, Syngenta, and BASF dominate the global seed market. Growers in Italy are saving and trading seeds outside that system.
MustGrow Biologics Corp.: MustGrow Receives First Milestone Payment from Bayer AG
Bayer AG has paid MustGrow the first development milestone payment. The MustGrow / Bayer AG License and Collaboration Agreement, signed in December 2023, covers soil applications of MustGrow's mus...
MustGrow Receives First Milestone Payment from Bayer AG
Bayer AG has paid MustGrow the first development milestone payment. The MustGrow / Bayer AG License and Collaboration Agreement, signed in December 2023, covers soil applications of MustGrow's mustard...
Bayer to present data from cardiovascular, kidney, stroke programs at ESC 2026
Bayer (BAYRY) today announced that 11 oral presentations across its cardiovascular, kidney, and secondary stroke prevention programs will be featured at the European Society of Cardiology, ESC, Congre...
Bayer to Present New Phase III Data from Its Cardiovascular, Kidney, and Stroke Clinical Trial Programs at ESC 2026
WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer Summary Bayer today announced that 11 oral presentations across its cardiovascular, kidney, and secondary stroke prevention programs will be featured at the Euro...
Zacks Industry Outlook Highlights Eli Lilly, Johnson & Johnson and Bayer
Pharma's 2026 recovery puts Bayer, Eli Lilly and Johnson & Johnson in focus as innovation and M&A offset pricing and patent headwinds.